Gemcitabine and pemetrexed disodium combinations in vitro and in vivo

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Pemetrexed disodium (ALIMTA) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. Pemetrexed disodium is broadly active in a wide variety of solid tumours, including non-small cell lung, breast, bladder, head and neck and ovarian cancers. Gemcitabine is a broadly active pyrimidine nucleoside antimetabolite, which is approved for the treatment of pancreatic and non-small cell lung cancers. Three preclinical studies have been reported that show cytotoxic synergy between gemcitabine and pemetrexed. Clinical activity with this combination has been observed in a phase I study, with partial responses in three of five patients previously treated for non-small cell lung cancer. An international phase II study of this combination in non-small cell lung cancer is ongoing.

Original languageEnglish (US)
Pages (from-to)103-105
Number of pages3
JournalLung Cancer
Volume34
Issue numberSUPPL. 4
DOIs
StatePublished - Jan 1 2001

Fingerprint

gemcitabine
Pemetrexed
Non-Small Cell Lung Carcinoma
Antimetabolites
Hydroxymethyl and Formyl Transferases
Pyrimidine Nucleosides
Head and Neck Neoplasms
Folic Acid
Ovarian Neoplasms
Urinary Bladder
Breast
Lung
Enzymes
In Vitro Techniques
Neoplasms

Keywords

  • Antifolate
  • Gemcitabine
  • Pemetrexed disodium
  • Thymidylate synthase

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Gemcitabine and pemetrexed disodium combinations in vitro and in vivo. / Adjei, Alex.

In: Lung Cancer, Vol. 34, No. SUPPL. 4, 01.01.2001, p. 103-105.

Research output: Contribution to journalArticle

@article{e67767a3228a41059b664b29aac32c79,
title = "Gemcitabine and pemetrexed disodium combinations in vitro and in vivo",
abstract = "Pemetrexed disodium (ALIMTA) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. Pemetrexed disodium is broadly active in a wide variety of solid tumours, including non-small cell lung, breast, bladder, head and neck and ovarian cancers. Gemcitabine is a broadly active pyrimidine nucleoside antimetabolite, which is approved for the treatment of pancreatic and non-small cell lung cancers. Three preclinical studies have been reported that show cytotoxic synergy between gemcitabine and pemetrexed. Clinical activity with this combination has been observed in a phase I study, with partial responses in three of five patients previously treated for non-small cell lung cancer. An international phase II study of this combination in non-small cell lung cancer is ongoing.",
keywords = "Antifolate, Gemcitabine, Pemetrexed disodium, Thymidylate synthase",
author = "Alex Adjei",
year = "2001",
month = "1",
day = "1",
doi = "10.1016/S0169-5002(01)00395-6",
language = "English (US)",
volume = "34",
pages = "103--105",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "SUPPL. 4",

}

TY - JOUR

T1 - Gemcitabine and pemetrexed disodium combinations in vitro and in vivo

AU - Adjei, Alex

PY - 2001/1/1

Y1 - 2001/1/1

N2 - Pemetrexed disodium (ALIMTA) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. Pemetrexed disodium is broadly active in a wide variety of solid tumours, including non-small cell lung, breast, bladder, head and neck and ovarian cancers. Gemcitabine is a broadly active pyrimidine nucleoside antimetabolite, which is approved for the treatment of pancreatic and non-small cell lung cancers. Three preclinical studies have been reported that show cytotoxic synergy between gemcitabine and pemetrexed. Clinical activity with this combination has been observed in a phase I study, with partial responses in three of five patients previously treated for non-small cell lung cancer. An international phase II study of this combination in non-small cell lung cancer is ongoing.

AB - Pemetrexed disodium (ALIMTA) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. Pemetrexed disodium is broadly active in a wide variety of solid tumours, including non-small cell lung, breast, bladder, head and neck and ovarian cancers. Gemcitabine is a broadly active pyrimidine nucleoside antimetabolite, which is approved for the treatment of pancreatic and non-small cell lung cancers. Three preclinical studies have been reported that show cytotoxic synergy between gemcitabine and pemetrexed. Clinical activity with this combination has been observed in a phase I study, with partial responses in three of five patients previously treated for non-small cell lung cancer. An international phase II study of this combination in non-small cell lung cancer is ongoing.

KW - Antifolate

KW - Gemcitabine

KW - Pemetrexed disodium

KW - Thymidylate synthase

UR - http://www.scopus.com/inward/record.url?scp=0035196094&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035196094&partnerID=8YFLogxK

U2 - 10.1016/S0169-5002(01)00395-6

DO - 10.1016/S0169-5002(01)00395-6

M3 - Article

C2 - 11742712

AN - SCOPUS:0035196094

VL - 34

SP - 103

EP - 105

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - SUPPL. 4

ER -